Dainippon Sumitomo Pharma Signs License Agreement for a Sedative Hypnotic Agent
Indiplon is a sedative hypnotic agent, for which NBI has worldwide development and commercialization rights. A registration program for indiplon has recently been completed in the U.S. for the treatment of insomnia.
An estimated 24 million people in Japan experience insomnia and the number is projected to increase under the current circumstances with social stress. Many of the patients have difficulty with initiation of sleep and a safer and more effective therapeutic agent is desired.
Indiplon is a potent and selective non-benzodiazepine medication targeting the GABA-A receptor. It is expected to be effective in the treatment of insomnia primarily with initiation of sleep, and to have safer profiles in terms of the reduction of adverse events, such as hang-over, amnesia and muscle relaxant, based on its shorter half-life and better receptor selectivity compared with the current short-acting insomnia drugs.
DSP has a large product portfolio in the CNS area, and expects to strengthen the lineups by this license agreement for indiplon. DSP will proceed with clinical development shortly with a view to launching indiplon in Japan as early as possible. DSP dedicates itself to contribute the treatment of insomnia and the improvement of the patients' QOL (Quality of Life).
About Neurocrine Biosciences, Inc.
Company Name: Neurocrine Biosciences, Inc.
Head office: 12790 El Camino Real, San Diego, CA 92130, USA
President and CEO: Gary A. Lyons
Founded: 1992
Activity: a product-based biopharmaceutical company focused on neurological and
endocrine diseases and disorders
Number of Employee: 260
Website: http://www.neurocrine.com/home_int.html
Company Name: Dainippon Sumitomo Pharma Co., Ltd.
President: Kenjiro Miyatake
Stock Exchange Listings: Tokyo, Osaka, Nagoya
Security Code number: 4506
Pharma Industry News Archive
2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
